Results 201 to 210 of about 2,113,360 (356)

Studies on the Promoting Action of a Catalyst Promoter and Carrier. III

, 1937
Shigeru Tsutsumi
openalex   +2 more sources

TERT Promoter Mutations in Familial and Sporadic Melanoma

Science, 2013
S. Horn, A. Figl, P. S. Rachakonda, C. Fischer, A. Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, E. Nagore, K. Hemminki, K. Hemminki, D. Schadendorf, Rajiv Kumar   +12 more
semanticscholar   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

Molecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren, Kathryn A. Wierenga, Frank M. Riemers, Elsbeth A. van Liere, Bart Westendorp   +4 more
wiley   +1 more source

Detection and Extraction of Potential Promoter/Enhancer Interactions in Genome of Cancer Patients using an Evolutionary Multi-Objective Algorithm

مجله انفورماتیک سلامت و زیست پزشکی, 2018
Introduction: Cancer, as one of the most common diseases, has influenced the health of many people. The main aim of this study was to present a multi-objective evolutionary algorithm.
Mohammadjavad Hosseinpoor, Hamid Parvin, Samad Nejatian, vahideh Rezaei   +3 more
doaj  

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source

Promoter Effects of Vanadium and Iron Oxides on Nickel-Catalysts Used for Kerosene Steam Reaction.

, 1961
Yoshiro Morita, Kenichi Yamamoto
openalex   +2 more sources

The nature of the potassium compound acting as a promoter in iron-alumina catalysts for ammonia synthesis [PDF]

, 1975
J VANOMMEN
openalex   +1 more source

CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma

Molecular Oncology, EarlyView.
CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan, Fenghua Tan, Jie Wu, Zhaoyang Zeng, Wenjia Guo, He Huang, Wei Xiong   +6 more
wiley   +1 more source

Catabolite-Insensitive Revertants of Lac Promoter Mutants

, 1970
Allen E. Silverstone, R. Rita Arditti, Boris Magasanik   +2 more
openalex   +1 more source